ProjectV–Arandomizedcontrolledprospectivestudyofthenext-generationprobiotic,V e i l l o n e l l aa t y p i c aFB0054,vsplaceboinhealthyadults
Version
Date:May16,2023
Protocol
Version: 
Protocol
Number:
01
FB004
Sponsor:
FitBiomics,
Inc. 
180
Varick
St 
6
th
Floor 
New
York,
NY
10014
Principal
Investigator:
Jonathan
Scheiman 
FitBiomics,
Inc 
180
Varick
St 
6
th
Floor 
Jonathan.scheiman@fitbiomics.com
Participating
Sites:
FitBiomics,
Single
Site
Study

TableofContentsTableofContents2
TableofAcronyms4
Title4
PrincipalInvestigator4
StudySynopsis4
BackgroundandRationale4
Objectives5
StudySupplement5
SubjectSelection5
InclusionCriteria5
ExclusionCriteria5
Researchequity6
VulnerablePopulations6
StudyProcedures6
Recruitment6
DetailsStudyProcedures6
Figure1.StudyProcedures7
Table1.SurveyDetails7
Table2.SurveySchedule8
CompletingResearchActivities8
Compensation8
Researchresultsorclinicalfindingsarisingfromresearchactivities8
Risk/SafetyInformation9
ForVeillonella:9
ForPlacebo:9
Otherrisksofstudyprocedures9
UnforeseenRisks9
RiskLevelDetermination9
AlternativestoParticipation9
ParticipantWithdrawalfromResearch/ResearchActivities9
Monitoring/ReportingofAE/SAE10
StudyOversight10
1
EthicalandRegulatoryStandard10
IRBReview/Ethics/InformedConsent11
StudyComplianceandReportingDeviations11
ConditionsforStudyTerminationorSuspension12
InformedConsent12
PrivacyAuthorization12
StateofCaliforniaHumanExperimentationRequirements13
DataManagement13
Confidentiality13
ReturnorClinicalUseofResearchResults13
IntendedUseoftheData14
Information/DataRetention,FutureUse,andSharing14
Publication14
BiostatisticalAnalysisPlan14
DataSource14
AnalysisObjectives14
AnalysisSets/Populations/Subgroups14
Endpoints15
HandlingofMissingValues15
StatisticalProcedures15
MeasurestoAdjustforConfounders16
QCPlans16
ProgrammingPlans16
InvestigatorConflictofInterest16
References17
2
TableofAcronyms
(inalphabeticalorder)
AcronymDefinition
AEAdverseEvent
BMIBodyMassIndex
CFRCodeofFederalRegulations
ChloeConsumerHealthLearningandOrganizingEcosystem
FDAFoodandDrugAdministration
GCPGoodClinicalPractice
GSEGeneralSelfEfficacy(aquestionnaire)
HIPAAHealthInsurancePortabilityandAccountabilityAct
ICHInternationalCouncilforHarmonization
IRBInstitutionalReviewBoard
I/EInclusion/Exclusion(criteria)
MFIMulti-dimensionalFatigueInventory(aquestionnaire)
NIHNationalInstituteofHealth
PIPrincipalInvestigator
QCQualityControl
SAESeriousAdverseEvent
USUnitedStates
3
StudySynopsis
Inthisstudy,weareassessingtheabilityofVeillonella(VeillonellaatypicaFB0054)todecreasefatigueandincreaseenergyinaheterogeneouscohortofhealthyadultscomparedtoplacebo.Studysubjectswillfilloutabaselinehealthandhabitsurveyfollowedbydailyandweeklysurveysoveratwoweekbaselineperiodtounderstandtheirbaselinehabits,fatigue,andenergylevels.Afterthis,subjectswilltakeonedailycapsuleorallyofoneoftwodosesofVeillonellaorplaceboforfourweeks,whileagainfillingoutbothdailyandweeklysurveys.Finally,therewillbeatwoweekwashoutperiodwithnosupplementationbutonlydailyandweeklysurveys.Attheendofthestudy,therewillbeafinalexperiencesurvey.
BackgroundandRationale
Veillonellaisanovelprobioticthatcanmetabolizelacticacidintopropionate,whichisanenergysourceforthebody[1,2].Inpreviousresearch,wehaveshownthatVeillonellacanimproveendurancecomparedtoplacebo.Inmousestudies,thosemicewhosupplementedwithV.atypicaran13%longerinarun-to-exhaustiontestthanthosemicewhoweregivenplacebo[1].Furthermore,inarandomizedcontrolledcrossoverpilotstudy,wecouldshowthatVeillonellaprevented78.7%oftheperformancedeclineobservedintheplacebogroupinarun-to-exhaustionmodel[3].WehavealsoconductedexperimentsthathaveresultedinthisproductbeingdeemedGenerallyRegardedAsSafe(GRAS)[4].
Therefore,webelievetheVeillonellaissafeandlikelytoprovidesignificantbenefitsintermsofimprovedendurance,increasedenergy,anddecreasedfatigue.Thisresearchstudyisdesignedtotestthathypothesis.FitBiomicsissponsoringthisstudytoconfirmtheseeffectsinabroaderpopulation.FitBiomicsisthefirstcompanytodevelopthistypeofbacteriaasaprobiotic,andthiswillbethelargeststudytestingthesafetyandefficacyofthisprobiotic.
Objectives
Thepurposeofthisresearchstudyisto:
●Testthesafetyandeffectivenessofthestudydrug,Veillonella(VeillonellaatypicaFB0054),anext-generationprobioticstrain.
●Identifythetypesofbenefitsobservedinabroadpopulation
StudySupplement
ThestudysupplementhereincludesoneoftwodosesofVeillonellaorplacebo.VeillonellacontainsVeillonellaatypicaFB0054astheactiveingredientwithmicrocrystallinecelluloseandhypromelloseasexcipients.Thetwodosesare15billioncfu(highdose)and7.5billioncfu(lowdose).Placebocapsulescontainmicrocrystallinecelluloseandhypromellose.BothVeillonellaandplaceboareencapsulatedinacid-resistantcapsulestoimprovedeliverytothelargeintestine,whichparticipantswilltakeorallyathomeonadailybasisforfourweeks.
4
SubjectSelection
ParticipantsinthisstudywillbehealthyadultsinterestedinusingVeillonellatoreducefatigueandincreaseenergy.Subjectswillbeexcludedfromthestudyiftheyhaveconditions,diseases,ormedicationsthatcouldresultinincreasedlikelihoodofAEsrelatedtoVeillonellause.
InclusionCriteria
●Maleorfemaleadultsaged18–65years.
●Willingandabletoprovidewritteninformedconsent.
●Abilityoftheparticipanttocomprehendthefullnatureandpurposeofthestudyincludingpossiblerisksandsideeffects.
●Agreementtocomplywiththeprotocolandstudyrestrictions.
●FluentinwrittenandspokenEnglish.
●IngoodgeneralhealthasjudgedbytheInvestigatorbasedonmedicalhistory.
●Willingtomaintaindailyexerciseanddiethabitsthroughoutthe8weekstudywithoutmakingmajorlifestylechanges.
●AbilitytouseapersonalsmartphonedeviceanddownloadtheChloeappbyPeopleScience
ExclusionCriteria
●Currentlypregnant,planningtobecomepregnant,orlactatingduringthenext12weeks
●Haveasignificantacuteorchroniccoexistingillness,disorder,orconditionthatcontraindicates,inthePrincipalInvestigator'sjudgment,entrytothestudy.
●Currentlytakingimmunosuppressivemedications.
●Isconsideredimmunosuppressedforanyreason.
●Currentlytakingmedicationsthatcouldimpairtheintegrityofthegutepithelia
●Hassymptomsoranillness,disorder,orcognitionthatimpairstheintegrityofthegutepithelia.
●Currentantibioticuseorplannedoralantibioticuseoverthecourseofthestudy.
●Investigatorbelievesthattheparticipantmaybeuncooperativeand/ornoncompliantandshouldthereforenotparticipateinthestudy.
ResearchequityThisresearchhasnodirectexclusionsrelatedtogender.Therearealsonodirectexclusionsrelatedtoraceorethnicity.
VulnerablePopulationsVulnerablepopulationsarenotspecificallytargetedinthisresearch.Racialandethnicminoritieswillbeincludedintheparticipantsbutarenotspecificallytargetedforinclusion.
StudyProcedures
SeeFigure1fordetailsofstudyprocedures.
Recruitmen tParticipantswillberecruitedtothestudyviaemailandsocialmedia.Interestedparticipantswillsignupthoughtheonlinestudylandingpage.Participantswillbechosenfromthepoolofsignupsbasedonthe
5
inclusionandexclusioncriteriaabove.Thereisnomaximumnumberofparticipants.Allthoseeligiblewillbeinvitedtoparticipate.However,weestimateupto1,000participantswillbeinvitedtoparticipateinthestudy.
DetailsStudyProceduresOnceparticipantsareinvitedtothestudy,theywillbesentanemailwithalinktotheChloeapplication,whichtheywilldownloadtotheirmobiledevice.Chloewillleadthemthroughadetaileddescriptionofthestudyandtheinformedconsentprocess.Atthispoint,theywillalsoconsenttosharingtheirfitnesstrackerdata,asanoption,iftheyhaveone.ThefitnesstrackerdatawillbeusedtoanswersleepquestionsandotherfitnesstrackerdatawillbestoredforanalysisbytheFitBiomicsteam.Onceinformedconsentisobtained,participantswillfilloutabaselinehealthandlifestylesurvey,wheretheywillalsosharetheirmailingaddress.Oncethissurveyiscompleted,theparticipantwillberandomizedtoahighdoseVeillonella(15billioncfu),lowdoseVeillonella(7.5billioncfu),orplaceboina4:4:2ratiorespectively.Thesecapsuleswillbemailedtotheparticipantduringthe2weekbaselineperiod.
Completionoftheinitialbaselinehealthandhabitsurveyinitiatesthe2weekbaselineperiod.Duringthisperiod,participantswillfilloutdailysurveysonsleep,energy,andbowelmovementsandweeklysurveysonotherbenefitsandadverseevents(AEs)theyhavenoticed(moredetailsonallsurveyscanbefoundinTables1and2).Onthefinaldayofthetwoweekbaseline,theywillalsofillouttheMultidimensionalFatigueInventory(MFI)andGeneralSelf-Efficacy(GSE)questionnaires.Atthispoint,participantswillbeginsupplementation.Participantswillsupplementwithonecapsuledailyfor4weeks.Duringthesupplementationphase,participantswillfilloutthesamedailyandweeklysurveys.Onthefinaldayofthesupplementationperiod,participantswillalsofillouttheMultidimensionalFatigueInventoryandGeneralSelf-Efficacyquestionnaires.Aftersupplementation,therewillbeatwoweekwashoutperiodtomonitorpatientsandtounderstandthelastingeffectofanybenefitstheyexperienced.Duringthewashoutperiod,participantswillagainfilloutthesamedailyandweeklysurveys.Onthefinaldayofthewashoutperiod,therewillbetwoadditionalsurveys:onewithsomeadditionalquestionsonchangesobservedthroughoutthestudyandoneofopenendedquestionsonthewholestudyexperience.
6
Figure1.StudyProcedures
Table1.SurveyDetails
SurveyNameSurveyDetailsNumberofQuestionsEstimatedTimetocompleteNumberofTimesUsedTotalsurveytime
StudysignupformFormusedtoexpressinterestinthestudy,includesquestionsonparticipan tdemographicsandtoinclude/excludeparticipan ts185minutes1X5minutes
BaselinesurveyIncludesquestionsondailyhabitsandlifestyleaswellasbaselinequestionsonnormalfatigueandenergylevels3110minutes1X10minutes
DailysurveyDailyassessmen toftheparticipan t’ssleep,energy,andbowelmovements4<1minute56X56minutes
WeeklySurveyParticipan tsareaskedtolookbackattheirweekandreporttheirfeelingsoffatigue,energy,mood,andhealth,aswellastheirexerciseandotherphysicalactivity185minutes8X40minutes
7

MFIAself-reportinstrumentdesignedtomeasurefatigue.Itcoversthefollowingdimensions:GeneralFatigue,PhysicalFatigue,MentalFatigue,ReducedMotivationandReducedActivity.205minutes2X10minutes
GSEPROMISself-efficacysurveydesignedtobenon-diseasespecificmeasureoflifemanagementandphysicalfunctioning4<1minute22minutes
EndofstudysurveyArepetitionofsomequestionsfromthebaselinesurveytoassesswhethertherehavebeensignificantchangesoverthecourseofthestudy4<1minute11minute
ExperiencesurveyMostlyopenendedquestionsonexperienceinthestudyitself,includingquestionsdesignedtoinformfuturemarketingofVeillonella65minutes15minutes
Totalsurveytime139minutes
Table2.SurveySchedule
RecruitmentPre-Week1Week1Week2Week3Week4Week5Week6Week7Week8
Studysignupform1X
Informedconsent1X
Baselinesurvey1X
DailysurveyDaily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)
Weeklysurvey1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek
MFI1Xatendofweek1Xatendofweek
GSE1Xatendofweek1Xatendofweek
Endofstudysurvey1Xatendofweek
8
Experiencesurvey1Xatendofweek
CompletingResearchActivities
Compensa tionParticipantswillreceivepointsintheChloemobileapptobeusedtowardanAmazonGiftCardandbeprovidedwithadiscountcodetopurchasetheNellaprobiotic.
ResearchresultsorclinicalfindingsarisingfromresearchactivitiesDuetothenatureofthestudy,itisunlikelythatresearchresultsorfindingsfromresearchactivitieswillresultinfurthermedical-relatedexpensesfortheparticipant.
Risk/SafetyInformation
Startinganewprobiotictendstoresultinmildandtransientgastrointestinalupset.Inourpreviouspilothumanstudies,wehaveobservedthesesymptoms,buttheyweremildenoughtonotinterferewitharun-to-exhaustionendpoint.Thesurveysusedinthisstudyincludeaquestiononpotentialsymptomsexperienced,whichwillallowustoidentifyadditionalpotentialAEsaswellasknownsideeffectsthatpersistlongerthanexpected.
ForVeillonella:Verycommon(greaterthanorequalto1/10)
●Mildgastrointestinalupsetincludingtemporaryincreasesingas,bloating,cramping,andnausea
●Nervousnessandincreasedfeelingsofanxiety
ForPlacebo:
●Noneknown
OtherrisksofstudyproceduresQuestionnaires:Thequestionsusedinthissurveymaycausetemporarydiscomfortordistresstotheparticipant.Thesurveyisdesignedtobesimpleandshortandisacommonlyusedtoolinclinicalstudies.Theparticipantmaychoosenottocompletethequestionnaire.
BreachofConfidentiality:Thereisminimalriskthatpeoplewhoarenotconnectedwiththisstudywilllearnoftheparticipant’sidentityorpersonalinformation.ThestudystaffwillbeGCPtrainedandwillutilizebestpracticeswhenusingthedataplatformtoensureparticipantprivacyprotections.
UnforeseenRisksTheremaybeotherrisksthatareunknown.Additionally,theremaybeunknownriskstoapregnancy,embryo,orfetusifyouoryourfemalepartnerbecomepregnant.
9
RiskLevelDeterminationTheriskstothestudyareminimalorunanticipatedduetoappropriatemitigationmeasures(e.g.breachofconfidentiality,lossofinternetaccess).Thisresearchmeetsthefederallydefineddefinitionofminimalrisk(45CFR46.102(j)).
AlternativestoParticipationTheindividualcanchoosenottoparticipate.
Participan tWithdrawalfromResearch/ResearchActivitiesResearchactivitiesarelimitedtofiveweeks.
Participantsmaywithdrawfromthestudyatanytimeandforanyreasonwithoutprejudice.Thewithdrawalmustbedocumented.
Monitoring/ReportingofAE/SAE
AEsandSAEswillbedetectedusingtheweeklysurveys.Onaweeklybasis,participantsareaskediftheyhavestoppedtakingtheproductduetosideeffects.Iftheyanswerintheaffirmative,theycanprovidemoreinformationonthesymptomsandtheirseverity.ParticipantscanalsoreportAEsandSAEstothestudystaffatanytimeviaphoneoremail.
AnAEisdefinedasanyreportedsideeffectoftheproductthatislikelyduetoVeillonellaitself.Basedonourpreviouswork,weanticipatemildandtransientgastrointestinalupsetaswellasmildanxietyaspossiblecommonAEs.
AnSAEisdefinedasanysevereand/orunexpectedsideeffectthatislifethreatening,requiresmedicalorsurgicalintervention,orisotherwiseanimportantmedicaleventforthepatient.SAEsarealsoAEsthatresultinhospitalization,disabilityorpermanentdamage,ordeath.ThesewillbereportedtotheFDA.
FitBiomicsisutilizingacompanycalledSafetyCallforAEmonitoringandreportinginthisstudy.SafetyCallwillprovideadverseeventmanagement,incidentdocumentation,andfirstaidadviceforbasicon-sitepatientmanagement,generalmedicalandclinicaltoxicologyconsultationforhealthcareproviders,andhealthandsafetyinformationtothestudyparticipants,customers,medicalpersonnel,andothers.Servicesareprovidedbytelephone24hoursaday,365daysayear.
SafetyCallwillalsoprovideadverseeventmanagementandincidentdocumentationfornon-telephonebasedcorrespondencesuchasconsumeremail,customerservicenotifications,internet-basedinquiriesandwrittencommunications.Theseservicesincludeaninitialprofessionalassessmentforhealthriskandtriage.SafetyCallwillrespondtoanyinquiriesitreceives,includingincidentsinvolvingeitherhumansoranimalsconsistentwithstandardofcarepractices.Aleadtoxicologistisavailablefrom9:00amto5:00pmCentralStandardTime,MondaythroughFriday.Anon-calltoxicologistisavailableafterhours.
SafetyCallwillalsomanagereportingofAEstotheFDA.IncompliancewiththeDietarySupplementandNonprescriptionDrugConsumerProtectionAct(Pub.L.109-462,120Stat.3469),anycorrespondenceorverbalnotificationofapotentialadverseevent(AE)inassociationwithadietarysupplementreceivedbyamanufacturerand/oritssubsidiarieswillbedocumentedaccordingtoFDAmandateddatacollectionguidelinesandallrecordsretainedforaminimumof6yearsforpotentialreviewbytheFDA.Those
10
adverseeventsmeetingtheFDAdefinedcriteriaforseriouswillbereportedtotheFDAwithin15-businessdaysusingtheFDAForm3500Aanditsaccompanyingdataelements.
StudyOversight
Thisstudywillbemadeavailableformonitoring,auditing,IRBreviewandregulatoryinspectionbyprovidingdirectaccesstostudyrelatedsourcedata.
EthicalandRegulatoryStandardThisstudywillbeconductedinconformancewiththeprinciplessetforthinTheBelmontReport:EthicalPrinciplesandGuidelinesfortheProtectionofHumanSubjectsofResearch(USNationalCommissionfortheProtectionofHumanSubjectsofBiomedicalandBehavioralResearch,April18,1979)andtheDeclarationofHelsinki.
ThisstudyistobeconductedincompliancewiththeIRBapprovedprotocolandaccordingtoapplicablefederal,state,localandtriballawsincludingthefollowing:
●USCodeofFederalRegulations(CFR)governingclinicalstudyconduct:Title45Part46–ProtectionofHumanSubjects
●USCodeofFederalRegulationsrelatingtotheHealthInsurancePortabilityandAccountabilityActof1996:Title45Part164–SecurityandPrivacy–SubpartE-
○SubpartE—PrivacyofIndividuallyIdentifiableHealthInformation
●StateofCaliforniaHealthandSafetyCode,Title17,forresearchconductedinCalifornia
Inaddition,thisstudyistobeconductedincompliancewithapplicablepoliciesandproceduresoftheAdvarraIRB,applicableinstitutionalresearchpoliciesandprocedures,applicableinstitutionalclinicalpoliciesandprocedures,andapplicableNIHpoliciesandprocedures.
IRBReview/Ethics/InformedConsentTheprotocol,informedconsentform(s),recruitmentmaterialsandallparticipantmaterialswillbesubmittedtotheAdvarraIRBforreviewandapproval.Approvalofboththeprotocolandtheconsentformmustbeobtainedbeforeanyparticipantisenrolled.AnyamendmentstotheprotocolorconsentmaterialswillrequirereviewandapprovalbytheIRBbeforethechangesareimplementedinthestudy.
Perthefederalregulationsat45CFR46andStateofCaliforniaHealthandSafetycode,Title17,mustreviewandapprovethisprotocolandtheinformedconsentprocessanditsdocumentspriortoinitiationofthestudy.Allinstitutional,NIH,Federal,andStateofCaliforniaregulationsmustbefulfilled.
AnydocumentsthattheIRBmayneedtofulfillitsresponsibilities(suchasprotocol,protocolamendments,consentforms,informationconcerningparticipantrecruitment,paymentorcompensationprocedures,orotherpertinentinformation)willbesubmittedtotheIRB.TheIRB’swrittenapprovalofthestudyprotocolandtheinformedconsentdocumentwillbeinthepossessionoftheinvestigatorbeforethestudyisinitiated.
Anyamendmenttotheprotocoldocumentandaccompanyinginformedconsentdocuments,asdevelopedandprovidedbythePI,willrequirereviewandapprovalbytheIRBofrecordbeforethechangesareimplementedinthestudy.
11
StudyComplianceandReportingDeviationsAdeviationisadivergencefromaspecificelementofaprotocolandthatoccurredwithoutpriorIRBapproval.Deviationsfromtheapprovedprotocolwillbeavoided,exceptwhennecessarytoeliminateanimmediatehazardtoaresearchparticipant.AlldeviationsfromtheprotocolwillbedocumentedinstudysourcedocumentsandpromptlyreportedtotheIRB.
Investigatorsmaydeviatefromtheprotocoltoeliminateimmediatehazardsfortheprotection,safety,andwell-beingofthestudysubjectswithoutpriorIRBapproval.Foranysuchdeviation,thePIwillnotifytheIRB,within5calendardaysofitsoccurrencebyelectronicsubmissionofadeviationnotice.
ConditionsforStudyTerminationorSuspensionThisstudywillbeterminatedprematurelyinthefollowingsituations:
●Thereareunforeseensafetyissuesorifotherstudiesarepublishedthatindicateapresenceofunanticipatedtoxicityrisksthatcannotbeadequatelyquantified.
●Theprotocolisdeterminedtonolongermeetstudyorsponsorobjectives.
ThestudyPIortheIRBmayterminateorsuspendthisstudyatanytime.Ifthestudyisprematurelyterminatedorsuspended,participantswillbeinstructedastowhethertheyshouldcompletesupplementation.Participantswillbemonitoredandcontinuefollowupfor2weeksaftertheystopsupplementationtoensuretheirsafetyandtocollectanyfinaldata.Allparticipantswhohavecompletedatleast50%ofsurveysatthetimethatthestudyisterminatedorsuspendedwillbeprovidedwithadiscountcodetopurchasetheNellaprobioticascompensation.
InformedConsentInformedconsentisaprocessthatisinitiatedpriortotheindividualagreeingtoparticipateinthestudyandcontinuesthroughoutstudyparticipation.Operationaldetailsspecifictotheconsentingprocessthatoccurspriortoanyresearchevaluations/interventionsaredescribedinSection6.0.
Allparticipantswillundergovirtualelectronicinformedconsentaftertheyaredeterminedtoqualifyforthestudy.Anelectronicinformedconsentdocumentwilldescribethenature,duration,purposeofthestudy,potentialrisks,alternativesandpotentialbenefits,andallotherIRBapprovedinformation.Inaddition,theexperimentalparticipant’sbillofrightsandtheHIPAAresearchauthorizationformwillbeprovided.Prospectiveresearchparticipantswillbeinformedthattheymaywithdrawfromthestudyatanytimeandforanyreasonwithoutprejudice.Prospectiveresearchparticipantswillbeaffordedsufficienttimetoconsiderwhethertoparticipateintheresearch.
Virtualinformedconsentwillbeconductedthroughtheapp-basedconsentformattheparticipant’sconvenience.Afterreadingtheconsent,participantswillbeabletocontactstudystaffaboutanystudyrelatedquestions.Oncetheprospectiveparticipantexpressesfullunderstanding,virtualinformedconsentwillbeobtainedthroughelectronicsignaturefromeithertheprospectiveparticipantbeforestudyparticipation.ThemethodofobtaininganddocumentingtheinformedconsentandthecontentsoftheconsentmustcomplywiththeICH-GCPandallapplicableregulatoryrequirements.AcopyofthesignedconsentdocumentwillbeavailabletotheparticipantwithintheChloeapp.Thesignedconsentmustbemaintainedbytheinvestigatorandavailableforinspectionbysponsordesignatedrepresentatives,orregulatoryauthorityatanytime.
12
PrivacyAuthoriz ationTheinformedconsentprocesswillincludeaprivacyauthorizationcompliantwith45CFR164.508(c)viatheinclusion/incorporationof:
-allcoreelementsspecifiedin508(c)(1)includingthesignatureoftheindividual(orrepresentative)anddateofsignature,-allrequiredstatementsspecifiedin508(c)(2)-theplainlanguagerequirementasspecifiedin508(c)(3),and-theprovisiontotheparticipant(orrepresentative)acopyofthesignedauthorization(508(c)(4)
StateofCaliforniaHumanExperimen tationRequirementsThisresearchinvolvesthecollectionofinformationviavalidatedquestionnairesandobtaininginformationfromthemedicalrecord.Researchactivitiesdonotencompassthosethatarerequisiteforaparticipanttobeinvolvedina“medicalexperiment”asdefinedbyCaliforniaStateLaw24174.The‘CaliforniaExperimentalSubject’sBillofRights’willbeadministeredaspartoftheinformedconsentprocess;aspartofthatprocessparticipantswillreceiveacopyofthe‘BillofRights’markedwiththeirsignature.
DataManagement
Studydatawillbestoredinsecurepassword-protectedservers.Studystaffwillde-identifyalldatapriortodataanalysis.DatawillbeanalyzedtocomparethesafetyandefficacyofVeillonellavsplaceboandbetweenthetwodifferentdosesofVeillonella.Wewillalsousethesedatatobetterunderstandthetypeofbenefitsdifferentsubsetsofparticipantstendtoexperienceaswellasthemagnitudeofthebenefitinthesesubpopulations.Theseresultswillbeusedtocreatepeer-reviewedpublications,academicandindustrypresentations,filepatents,andpotentiallydevelopnewinnovativemicrobiomeproductslikeprobiotics.Participantswillnotbenotifiedofanyoftheseuses.
Confidentiality
Alldocumentsandelectronicdatawillbestoredonsecure,password-protectedcomputers.Participantconfidentialitywillbestrictlyheldintrustbytheinvestigators,studypersonnel,andsponsor.Noidentifierswillbeusedinanysubsequentpublicationoftheseresults.
Recordsofparticipationinthisstudywillbeheldconfidentialexceptwhensharingtheinformationisrequiredbylaworasdescribedinthisinformedconsent.TheInvestigator,thesponsororpersonsworkingonbehalfofthesponsor,andundercertaincircumstances,theUSFDAandtheIRBwillbeabletoinspectandcopyconfidentialstudy-relatedrecordsandidentifysubjectsbyname.Thismeansthatabsoluteconfidentialitycannotbeguaranteed.Thisdoesnotlimitthedutyoftheresearchersandotherstoprotectparticipants’privacy.Studyrecordsincludingconfidentialinformationaboutstudysubjectscollectedduringthestudywillbekeptatasecurelocationorserver.Iftheresultsofthisstudyarepublishedorpresentedatmeetings,participantswillnotbeidentified.
13
Adescriptionofthisclinicaltrialwillbeavailableonhttp://www.ClinicalTrials.gov,asrequiredbyU.S.Law.ThisWebsitewillnotincludeinformationthatcanidentifyparticipants.Atmost,theWebsitewillincludeasummaryoftheresults.
ReturnorClinicalUseofResearchResultsParticipantswillbeshowntheirstudydatainrealtimeastheygothroughthedatavisualizationmodulesintheChloeplatform.
Researchresultswillbesharedwithparticipantsatcompletionofdataanalysis.Theresultsofthisresearchmayhelptheparticipantmakedecisionsinfutureproductpurchasesandparticipateinfutureresearchstudies.
Therearenoanticipatedburdensorfinancialobligationstoresearchsubjects.
IntendedUseoftheData
Information/Da taRetention,FutureUse,andSharingThedatacollectedaspartofthisstudywillbeusedtoassessthesafetyandefficacyofVeillonellainthispopulation.Thesedatamaybeusedinpeer-reviewedmanuscripts,researchpresentations,andothermaterialstopromoteFitBiomicsanditsplatform,ortodevelopnewproducts.Alldatawillbedeidentifiedpriortoanypublicationorpresentation.Priortothecompletionofthisresearch,informationwillbecoded,destroyed,de-identified,orprovidedtoaprivacyofficer.
PublicationThepublicationorpresentationofanystudyresultsshallcomplywithallapplicableprivacylaws,including,butnotlimitedto,theHealthInsurancePortabilityandAccountabilityActof1996.Neitherthecompletenoranypartoftheresultsofthestudycarriedoutunderthisprotocol,noranyoftheinformationprovidedbythesponsorforthepurposesofperformingthestudy,willbepublishedorpassedontoanythirdpartywithoutthewrittenapprovaloftheStudyPI.Anyinvestigatorinvolvedwiththisstudyisobligatedtoprovidethesponsorwithalldataderivedfromthestudy.
BiostatisticalAnalysisPlan
DataSourceThesourceofthedataistheresultsofthequestionnairesfilledoutthroughtheChloeappaswellastheoptionalfitnesstrackerdatacollectedoverthecourseofthestudy.
AnalysisObjectiv esThegoalsofthisanalysisaretoidentifywhethertherearestatisticallysignificantdifferencesineffectsbetweentheplaceboandVeillonellagroupsaswellasbetweenthehighandlowdoseVeillonellagroups.Furthermore,foranydifferencesthatareobserved,wewouldliketounderstandwhetherthereareanydemographicorotherparticipantcharacteristicsthatmaybeassociatedwithbenefitsorsideeffectsexperiencedbytheparticipants.
14
AnalysisSets/Populations/SubgroupsThethreegroupscomparedinthisstudyarehighdoseVeillonella,lowdoseVeillonella,andplacebo.
Inaddition,weplantoseparatelyanalyzeresultsbygender,age,baselineexercisehabits,healthhistory,previousprobioticexperience,sleephabits,andotherlifestylefactors.
Forthoseparticipantswhosharefitnesstrackerdata,thefitnesstrackerdatasharedthroughtheChloeappwillbeanalyzedinconjunctionwithsurveydataseparatelyfromthosewhodidnotsharefitnesstrackerdata.
Endpoin tsTheprimaryendpointsanalyzedinthisstudyare:
-Changeinreportedphysicalfatigue-Changeinmental/emotionalfatigue-ChangeinMFI
Thesecondaryendpointsanalyzedinthisstudyare:
-Changeinreportedsleepquality-Changeinfrequencyofreportedphysicalactivity-Changeinintensityofreportedphysicalactivity-Changeinreportedexercise-Changeinrecoverytime-Changeinenergylevel
Theexploratoryendpointsanalyzedinthisstudyare:
-Changesinfitnesstrackerdata-Changeinreportedbowelmovements-ChangeinGSE-Changeinreportedmood-Changeinreporteddigestivehealth-Changeinreportedgeneralhealth-ChangeinBMI,weight,orwaistcircumference
HandlingofMissingValuesTherewilllikelybemissingvaluesrelatedtoincompleteormissingsurveys.Participantswillonlybeincludedintheanalysisiftheycompletedatleast50%ofweeklysurveysduringeachtimeperiod:baseline,supplementation,andwashout.Valueswillbebinnedlongitudinallysuchthateachparticipantincludedintheanalysishasadatapointassociatedwitheachbin.Iftherearemultiplevaluesassociatedwithaparticipantinabin,themeanofthosevalueswillbeusedfortheanalysis.
StatisticalProceduresThemajorityofprimaryandsecondaryendpointsforthisstudyarequestionsonthesurveywhichconsistofratingscales(generally1-5or1-9).SignificantdifferencesbetweengroupsfortheseendpointswillbeassessedusinganindependentTtestorMann-WhitneyUtestdependingontheobserved
15
distributionofthedata.Forsignificantchangesovertimewithinthesamegroup,adependentTtestwillbeused.
Fordifferencesbetweengroupsintermsofprimaryandsecondaryendpointsthatmeasureachangeintime(e.g.timetorecoveryindaysorhoursofsleep),anindependentTtestorMann-WhitneyUtestwillbeused,dependingontheobserveddistributionofthedata.Forsignificantchangesovertimewithinthesamegroup,adependentTtestwillbeused.
Toidentifydemographicsassociatedwithanyparticularresponse(benefitorsideeffects),wewillusethedemographic,healthhistory,andlifestyleinformationcollectedinthesurveystobuildanunsupervisedmachinelearningalgorithm(e.g.RandomForestClassifier).Ifwecanbuildonethateffectivelyclassifiestheresponse(AUC>0.7),wewillidentifythemodel’smostimportantfeatures.Toconfirmthatthesefeaturesaresignificantlyassociatedwithresponse,wewilluseanindependentTtesttoassesssignificantdifferencesbetweenresponseandnon-response.
Forallotherexploratoryendpointsincludingtheoptionalfitnesstrackerdata,thedatatypeanddistributionofthatdatawilldeterminethestatisticalanalysisused.
MeasurestoAdjustforConfoundersForalldataandendpoints,datacanbenormalizedtothebaselinecollectedvalues,andchangeinvalueatdifferenttimepointscanbecomparedusingthestatisticaltestsdescribedabove.
Inaddition,thereisaquestionincludedintheweeklysurveysassessinghowparticipantsaregenerallyfeelingabouttheirlife,whichtheyrespondtousingaratingscalefrom1(pessimistic)to9(optimistic).Ifnecessary,wecannormalizetheweeklysurveydatausingthisratingtoconfirmthatparticipantlifeandstressoutsidethestudyarenotaffectinghowtheyrespondtothesurveys.
QCPlansAllanalyseswillbeperformedbyastudybioinformaticianordatascientist.AllcodeusedfortheanalysiswillbesavedusingversioncontrolsoftwaresuchasGitintheformatorPythonnotebooks.Thesenotebookswillbereviewedbyotherstudystaffforerrorsandcertifiedthatanalysesarecorrectpriortoanywrittenororalreports,presentations,orpublicationsontheresultsofthestudy.
ProgrammingPlansAllcodefortheseanalyseswillbewrittenusingPython3inJupyternotebooks.Thepandaslibrarywillbeusedforimportingthedata,manipulatingitinadataframe,andexportingitasexcelorcomma-separatedfiles.TheNumpyandScipylibrarieswillbeusedforallstatisticalanalysisandtheSci-KitLearnlibrarywillbeusedformachinelearninganalyses.MatplotlibandSeabornlibrarieswillbeusedforvisualizationofthedataasgraphsandcharts.
InvestigatorConflictofInterest
Investigatorswilldiscloseanyconflictofinterest.
Anyinvestigatorwhohasaconflictofinterestwiththisstudy(patentownership,royalties,orfinancialgaingreaterthantheminimumallowablebytheirinstitution,etc.)musthavetheconflictreviewedbyaproperlyconstitutedConflictofInterestCommitteewithaCommittee-sanctionedconflictmanagement
16
planthathasbeenreviewedandapprovedbythestudySponsorpriortoparticipationinthisstudy.Allinvestigatorswillfollowtheconflictofinterestpolicy.
R e f e r e n c e s
1.ScheimanJ,LuberJM,ChavkinTA,MacDonaldT,TungA,PhamL-D,etal.Meta’omicanalysisofeliteathletesidentifiesaperformance-enhancingmicrobethatfunctionsvialactatemetabolism.NatMed.2019;25:1104–9.
2.NgSK,HamiltonIR.CarbondioxidefixationbyVeillonellaparvulaM4anditsrelationtopropionicacidformation.CanJMicrobiol.1973;19:715–23.
3.GrossK,SantiagoM,KriegerJM,HageleAM,ZielinskaK,ScheimanJ,etal.AcuteImpactofVeillonellaatypicaFB0054SupplementationonExercisePerformanceandLactateChanges:ARandomized,CrossoverPilot.Nutrients.InReview.
4.PreeceKE,GlávitsR,MurbachTS,EndresJR,HirkaG,VértesiA,etal.SafetyevaluationofVeillonellaatypicaFB0054withgenotoxicityandsubchronictoxicologicalstudies.JApplToxicolJAT.2023;43:808–27.
17